Long-term Incidence and Risk Factors of Macular Fibrosis, Macular Atrophy, and Macular Hole in Eyes with Myopic Neovascularization

Cicinelli, Maria Vittoria; Franca, Lamberto La; Felice, Elisabetta De; Rabiolo, Alessandro; Marchese, Alessandro; Parodi, Maurizio Battaglia; Introini, Ugo; Bandello, Francesco

doi:10.1016/j.oret.2022.06.009

Cited by 5 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Up to date, the mainstream treatment for those disorders is anti-vascular drug administration, such as bevacizumab, ranibizumab and aflibercept, etc [2][3][4] . However, in addition to the pronounced antivascular effect, the ensuing fibrosis may also bring about many severe problems, like retinal pigment epithelium tear, tractional retinal detachment and so on [5][6][7][8][9][10] . The normal angiogenesis process requires a fine balance between the pro-vascular and anti-vascular biomolecules, including angiopoietin 2, vascular endothelial growth factor (VEGF), tumor necrosis factor α (TNFα), platelet derived growth factor (PDGF), and basic fibroblast growth factor (bFGF), etc [11] .…”

Section: Introductionmentioning

confidence: 99%

Effect of a novel tyrosine kinase inhibitor nintedanib on bFGF and VEGF concentrations in a rabbit retinal vein occlusion model

Fang,

Qian,

et al. 2023

Int J Ophthalmol

View full text Add to dashboard Cite

AIM: To evaluate whether a novel tyrosine kinase inhibitor nintedanib could inhibit basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) simultaneously for retinal vascular disease in vivo. METHODS: After a laser induced rabbit retinal vein occlusion (RVO) model was made, 0.5 mg of nintedanib was injected intravitreally in the left eye on the third day while the right eye was as a control. Intracameral samples were taken on the day before laser treatment and days 1, 3, 7, 14, 21, and 28 after treatment. Enzyme-linked immunosorbent assay (ELISA) was used to test the bFGF and VEGF-A concentrations in the aqueous humor. RESULTS: Both bFGF and VEGF-A rose significantly on the third day after laser treatment in both eyes. In the control eye the bFGF concentration peaked on the 14th day while the VEGF-A concentration dropped rapidly soon after the third day. After nintadanib injection in the study eye, both bFGF and VEGF-A showed a significant reduction on the 4th day (7th day after laser treatment) when compared to the control eye, and kept on low level in the following several weeks. CONCLUSION: Intravitreal injection of nintedanib can inhibit the expression of bFGF and VEGF in the process of RVO model to a certain extent, which is expected to become a new method for the treatment of retinal vascular diseases or fibrotic diseases.

show abstract

Section: Introductionmentioning

confidence: 99%

Effect of a novel tyrosine kinase inhibitor nintedanib on bFGF and VEGF concentrations in a rabbit retinal vein occlusion model

Fang,

Qian,

et al. 2023

Int J Ophthalmol

View full text Add to dashboard Cite

show abstract

“…Через год после появления мХНВ следует периодически проводить исследование на аутофлуоресценцию глазного дна для выявления связанной с ней макулярной атрофии [22]. В дальнейшем рекомендуется регулярное диспансерное наблюдение один раз в 6-12 мес с возможным проведением внеплановых осмотров при появлении любых новых зрительных расстройств [23].Наиболее частыми причинами снижения зрения у пациентов с мХНВ, получающих анти-VEGF терапию, в отдаленном периоде являются фиброз, атрофия и формирование макулярного разрыва, частота развития которых в течение пяти лет после начала лечения составляет 34, 26 и 8% соответственно [24].…”

unclassified

On classification approaches, terminology and modern principles of treatment of pathologies associated with high myopia. Part 3. Approaches to monitoring and treatment of patients

Нероев

Zaytseva

Тарутта

et al. 2023

Rossijskij oftalʹmologičeskij žurnal

View full text Add to dashboard Cite

High myopia is a common ametropia associated with a significant risk of multiple comorbidities. Decreased visual functions of myopic patients may be caused by non-specific diseases such as cataracts, glaucoma and rhegmatogenous retinal detachment, which are very likely in myopia. Yet especially important are the specific changes such as atrophic, traction and neovascular manifestations of pathological myopia, the totality of which is defined as myopic macular degeneration or myopic maculopathy. The review highlights current approaches to the diagnosis and treatment of various diseases associated with high myopia, including original schemes for managing patients with myopic choroidal neovascularization and myopic traction maculopathy, developed by experts from the Expert Council on Retinal and Optic Nerve Diseases of the Russian nationwide public body Association of ophthalmologists, and includes an information leaflet for patients.

show abstract

Incidence and Risk Factors of Second Eye Involvement in Myopic Macular Neovascularization

Ravenstijn

Klaver

Yzer

2023

Ophthalmology Retina

View full text Add to dashboard Cite

Long-term Incidence and Risk Factors of Macular Fibrosis, Macular Atrophy, and Macular Hole in Eyes with Myopic Neovascularization

Cited by 5 publications

References 35 publications

Effect of a novel tyrosine kinase inhibitor nintedanib on bFGF and VEGF concentrations in a rabbit retinal vein occlusion model

Effect of a novel tyrosine kinase inhibitor nintedanib on bFGF and VEGF concentrations in a rabbit retinal vein occlusion model

On classification approaches, terminology and modern principles of treatment of pathologies associated with high myopia. Part 3. Approaches to monitoring and treatment of patients

Incidence and Risk Factors of Second Eye Involvement in Myopic Macular Neovascularization

Contact Info

Product

Resources

About